Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.

PHASE2CompletedINTERVENTIONAL
Enrollment

212

Participants

Timeline

Start Date

December 18, 2012

Primary Completion Date

January 27, 2016

Study Completion Date

October 31, 2022

Conditions
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
Interventions
DRUG

Selumetinib 75 mg

Three selumetinib capsules (Hyd-Sulfate) 25 mg will be administered orally, twice daily, (75 mg dose bd) on an uninterrupted schedule.

DRUG

Docetaxel 75 mg/m2

Docetaxel 75 mg/m2 will be administered intravenously on day 1 of each 21 day cycle.

DRUG

Docetaxel 60 mg/m2

Docetaxel 60 mg/m2 will be administered intravenously on day 1 of each 21 day cycle.

DRUG

Placebo

Three placebo capsules will be administered orally uninterrupted twice daily.

Trial Locations (68)

1032

Research Site, Budapest

1121

Research Site, Budapest

1122

Research Site, Budapest

1233

Research Site, Sofia

1303

Research Site, Sofia

1330

Research Site, Sofia

1756

Research Site, Sofia

2045

Research Site, Törökbálint

3000

Research Site, Vratsa

3529

Research Site, Miskolc

3780

Research Site, Edelény

4000

Research Site, Plovdiv

4004

Research Site, Plovdiv

4400

Research Site, Nyíregyháza

7400

Research Site, Kaposvár

8000

Research Site, Székesfehérvár

9010

Research Site, Varna

9024

Research Site, Győr

10011

Research Site, New York

10032

Research Site, New York

11501

Research Site, Mineola

19107

Research Site, Philadelphia

22927

Research Site, Großhansdorf

29609

Research Site, Brest

30318

Research Site, Atlanta

33028

Research Site, Hollywood

37203

Research Site, Nashville

45122

Research Site, Essen

47441

Research Site, Moers

59000

Research Site, Lille

60637

Research Site, Chicago

63003

Research Site, Clermont-Ferrand

65199

Research Site, Wiesbaden

69310

Research Site, Pierre-Bénite

70072

Research Site, Marrero

73730

Research Site, Esslingen am Neckar

74245

Research Site, Löwenstein

76137

Research Site, Karlsruhe

80045

Research Site, Aurora

90404

Research Site, Santa Monica

94805

Research Site, Villejuif

97080

Research Site, Würzburg

02215

Research Site, Boston

17033-0850

Research Site, Hershey

14784-400

Research Site, Barretos

70390-055

Research Site, Brasília

98700-000

Research Site, Ijuí

90035-003

Research Site, Porto Alegre

90619-900

Research Site, Porto Alegre

91350-200

Research Site, Porto Alegre

09060-650

Research Site, Santo André

15090-000

Research Site, São José do Rio Preto

01221-020

Research Site, São Paulo

01246-000

Research Site, São Paulo

04039-002

Research Site, São Paulo

F-14033

Research Site, Caen

5223 GZ

Research Site, 's-Hertogenbosch

1066 CX

Research Site, Amsterdam

1081 HV

Research Site, Amsterdam

4624 VT

Research Site, Bergen op Zoom

6202 AZ

Research Site, Maastricht

80-219

Research Site, Gdansk

86-300

Research Site, Grudziądz

31-202

Research Site, Krakow

10-357

Research Site, Olsztyn

61-848

Research Site, Poznan

34-200

Research Site, Sucha Beskidzka

70-891

Research Site, Szczecin

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY